Physician profile
John Mues
NPI 1184718744
$979.95
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $156 · 2021: $394.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $279.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $185.03 | 2019-2021 | |
| Abbvie INC. | $129.79 | 2021 | |
| Astellas Pharma US INC | $79.09 | 2019-2021 | |
| Novo Nordisk INC | $70.25 | 2019 | |
| Pfizer INC. | $39.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.15 | 2019-2020 | |
| Amgen INC. | $27.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $19.33 | 2021 | |
| Abbott Laboratories | $18.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.55 | 2019 | |
| Allergan, INC. | $15.00 | 2020 | |
| Lilly USA, LLC | $13.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.88 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mues listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.